Jan. 26, 2021 12:00 UTC Funding Supports Aclipse Therapeutics and Sheffield Institute of Translational Neurosciences Development of M102 in Amyotrophic Lateral Sclerosis RADNOR, Pa.--(BUSINESS WIRE)-- Aclipse Therapeutics (Aclipse or the Company), a private biopharmaceutical company, today announced that the Company and its collaborator, The Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield in the United Kingdom (UK), were awarded a drug development research grant of 1.6 million (approximately US $2.2 million) from the UKs Medical Research Council (MRC), one of the largest funders of medical research worldwide, to support the translational development of M102. Continue reading →

Greg Gowe at the Vancouver airport, on his way to a clinical trial appointment in Montreal in November 2020. Continue reading →

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025 released by MarketQuest.biz is a specialized and in-depth study of the market with a detailed focus on the global market trend analysis. The report aims to provide an overview of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market with detailed market segmentation by component, deployment, organization size, the end-user. The market is scrutinized in terms of market size, market share, status, trends, competitive scenario, and potential growth opportunities with a forecast till 2025 Continue reading →

A muscle cramp is a painful tightness in a muscle due to a sudden, involuntary contraction. Various factors may contribute to muscle cramping, but the underlying cause is often unclear Continue reading →

The shift means the citys nonessential curfew has been lifted and bars and restaurants can now sit up to six guests at a table, according to City Hall. But indoor dining and indoor events are limited to 25% capacity or 25 people per space Continue reading →

The starter online wellness program offers patients the opportunity to work with a health coach to assist them in improving and self-managing their health from home. Continue reading →

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Cutting edge is, for once, a truly apt description when it comes to gene editing both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome. Continue reading →